← 홈

림프종

587개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 587개
ADCBiologicstalePfizerPhase 2

BrECADD (BrECADD)

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma (Category)

#HodgkinLymphomaCategory#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 5상태 RECRUITING
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 ACTIVE
CGTBiologicstaleTakedaPhase 2

CD19-CAR-T2 Cells (CD19-CAR-T2 Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 5상태 ACTIVE
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Larotrectinib Sulfate (Larotrectinib Sulfate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 60%임상시험 5상태 RECRUITING
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (RJMty19, RJMty19 (CD19-CAR-DNT cells))

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

SAR3419 (SAR3419)

Diffuse Large B-cell Lymphoma · Acute Lymphocytic Leukaemia

#AcuteLymphocyticLeukaemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 5상태 ACTIVE
CGTBiologicstaleShanghai Unicar-Therapy Bio-med…Phase 2

ssCART-19 (ssCART-19)

B Cell Lymphoma · B Cell Lymphoma

#BCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 5상태 RECRUITING
AntibodystaleActinium PharmaceuticalsPhase 1

131-I Apamistamab (131-I Apamistamab)

B-ALL; DLBCL · B-ALL

#B-ALL#Antibody#Phase1#항체#면역항체+3
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
CGTBiologicstaleStichting Hemato-Oncologie voor…Phase 2

ARI-0001 (ARI-0001)

NHL; DLBCL - Diffuse Large B Cell Lymphoma · NHL

#NHL#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
CGTBiologicstaleThe Affiliated Hospital of Xuzh…Phase 2

Anti-CD56 CAR T (Anti-CD56 CAR T)

Extranodal NK T Cell Lymphoma; NK-Cell Leukemia · Extranodal NK T Cell Lymphoma

#ExtranodalNKTCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.33%임상시험 4상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 ACTIVE
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 DISCONTINUED
ADCBiologicstaleRochePhase 3

polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
CGTBiologicstaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
AntibodyBiologicstaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING

10 / 30 페이지

← 이전다음 →